secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108280
Event type: debt
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen amends debt agreement, reduces minimum cash requirement from $18.75M to $15M
--------------------------------------------------------------------------------

- Fourth Amendment to Financing Agreement with Morgan Stanley Tactical Value lenders executed August 12, 2025.
- Minimum qualified cash balance reduced from $18.75 million to $15.0 million effective immediately.
- Prior amendments dated May 8, June 5, and July 14, 2025 indicate ongoing covenant adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025108280/0000950170-25-108280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025108280/fgen-20250812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer